Transcriptional changes associated with recovery from heart failure in the SHR

Journal of Molecular and Cellular Cardiology

Volumn 49, Issue 3, 2010, Pages 390-401

  Brooks, Wesley W ^a,b   Shen, Steven ^b   Conrad, Chester H ^a,b   Goldstein, Ronald H ^a,b   Deng, Lingyi Lynn ^a,b   Bing, Oscar H L ^a,b  

^a VA BOSTON HEALTHCARE SYSTEM   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin converting enzyme inhibition; Cardiac hypertrophy; Gene expression profiling; Heart failure; Hypertension; Phenylbutyrate

Indexed keywords

ARYLBUTYRIC ACID DERIVATIVE; CAPTOPRIL; GUANINE NUCLEOTIDE BINDING PROTEIN; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; FATTY ACID METABOLISM; GENE EXPRESSION PROFILING; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE VOLUME; HYPOXIA; ION TRANSPORT; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; SIGNAL TRANSDUCTION; SPONTANEOUSLY HYPERTENSIVE RAT; SURVIVAL TIME; TRANSCRIPTION REGULATION; UNINDEXED SEQUENCE;

ANIMALIA; RATTUS;

EID: 77955271446     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2010.06.002     Document Type: Article

References (55)

1. Pfeffer J.M., Pfeffer M.A., Mirsky I., Braunwald E. Regression of left ventricular hypertrophy and prevention of left ventricular dysfunction by captopril in the spontaneously hypertensive rat. Proc Natl Acad Sci U S A May 1982, 79(10):3310-3314.
2. Brooks W.W., Bing O.H., Conrad C.H., O'Neill L., Crow M.T., Lakatta E.G., et al. Captopril modifies gene expression in hypertrophied and failing hearts of aged spontaneously hypertensive rats. Hypertension Dec 1997, 30(6):1362-1368.
3. Brooks W.W., Bing O.H., Robinson K.G., Slawsky M.T., Chaletsky D.M., Conrad C.H. Effect of angiotensin-converting enzyme inhibition on myocardial fibrosis and function in hypertrophied and failing myocardium from the spontaneously hypertensive rat. Circulation Dec 2 1997, 96(11):4002-4010.
4. Hwang J.J., Allen P.D., Tseng G.C., Lam C.W., Fananapazir L., Dzau V.J., et al. Microarray gene expression profiles in dilated and hypertrophic cardiomyopathic end-stage heart failure. Physiol Genomics Jul 12 2002, 10(1):31-44.
5. Steenman M., Chen Y.W., Le Cunff M., Lamirault G., Varro A., Hoffman E., et al. Transcriptomal analysis of failing and nonfailing human hearts. Physiol Genomics Jan 15 2003, 12(2):97-112.
6. Sihag S., Cresci S., Li A.Y., Sucharov C.C., Lehman J.J. PGC-1alpha and ERRalpha target gene downregulation is a signature of the failing human heart. J Mol Cell Cardiol Feb 2009, 46(2):201-212.
7. Wellner M., Dechend R., Park J.K., Shagdarsuren E., Al-Saadi N., Kirsch T., et al. Cardiac gene expression profile in rats with terminal heart failure and cachexia. Physiol Genomics Feb 10 2005, 20(3):256-267.
8. Ueno S., Ohki R., Hashimoto T., Takizawa T., Takeuchi K., Yamashita Y., et al. DNA microarray analysis of in vivo progression mechanism of heart failure. Biochem Biophys Res Commun Aug 8 2003, 307(4):771-777.
9. Kong S.W., Bodyak N., Yue P., Liu Z., Brown J., Izumo S., et al. Genetic expression profiles during physiological and pathological cardiac hypertrophy and heart failure in rats. Physiol Genomics Mar 21 2005, 21(1):34-42.
10. Schiekofer S., Shiojima I., Sato K., Galasso G., Oshima Y., Walsh K. Microarray analysis of Akt1 activation in transgenic mouse hearts reveals transcript expression profiles associated with compensatory hypertrophy and failure. Physiol Genomics Oct 11 2006, 27(2):156-170.
11. Sakata Y., Chancey A.L., Divakaran V.G., Sekiguchi K., Sivasubramanian N., Mann D.L. Transforming growth factor-beta receptor antagonism attenuates myocardial fibrosis in mice with cardiac-restricted overexpression of tumor necrosis factor. Basic Res Cardiol Jan 2008, 103(1):60-68.
12. Gao Z., Xu H., DiSilvestre D., Halperin V.L., Tunin R., Tian Y., et al. Transcriptomic profiling of the canine tachycardia-induced heart failure model: global comparison to human and murine heart failure. J Mol Cell Cardiol Jan 2006, 40(1):76-86.
13. Sharma U.C., Pokharel S., Evelo C.T., Maessen J.G. A systematic review of large scale and heterogeneous gene array data in heart failure. J Mol Cell Cardiol Mar 2005, 38(3):425-432.
14. Garnier A., Fortin D., Delomenie C., Momken I., Veksler V., Ventura-Clapier R. Depressed mitochondrial transcription factors and oxidative capacity in rat failing cardiac and skeletal muscles. J Physiol Sep 1 2003, 551(Pt 2):491-501.
15. Lei B., Lionetti V., Young M.E., Chandler M.P., d'Agostino C., Kang E., et al. Paradoxical downregulation of the glucose oxidation pathway despite enhanced flux in severe heart failure. J Mol Cell Cardiol Apr 2004, 36(4):567-576.
16. Strom C.C., Aplin M., Ploug T., Christoffersen T.E., Langfort J., Viese M., et al. Expression profiling reveals differences in metabolic gene expression between exercise-induced cardiac effects and maladaptive cardiac hypertrophy. FEBS J Jun 2005, 272(11):2684-2695.
17. Stanley W.C., Recchia F.A., Lopaschuk G.D. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev Jul 2005, 85(3):1093-1129.
18. Ingwall J.S. Energy metabolism in heart failure and remodelling. Cardiovasc Res Feb 15 2009, 81(3):412-419.
19. Taegtmeyer H. Cardiac metabolism as a target for the treatment of heart failure. Circulation Aug 24 2004, 110(8):894-896.
20. Lewandowski E.D., Kudej R.K., White L.T., O'Donnell J.M., Vatner S.F. Mitochondrial preference for short chain fatty acid oxidation during coronary artery constriction. Circulation Jan 22 2002, 105(3):367-372.
21. Huss J.M., Kelly D.P. Mitochondrial energy metabolism in heart failure: a question of balance. J Clin Invest Mar 2005, 115(3):547-555.
22. Young M.E., McNulty P., Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes: Part II: Potential mechanisms. Circulation Apr 16 2002, 105(15):1861-1870.
23. Hajri T., Ibrahimi A., Coburn C.T., Knapp F.F., Kurtz T., Pravenec M., et al. Defective fatty acid uptake in the spontaneously hypertensive rat is a primary determinant of altered glucose metabolism, hyperinsulinemia, and myocardial hypertrophy. J Biol Chem Jun 29 2001, 276(26):23661-23666.
24. Kasumov T., Brunengraber L.L., Comte B., Puchowicz M.A., Jobbins K., Thomas K., et al. New secondary metabolites of phenylbutyrate in humans and rats. Drug Metab Dispos Jan 2004, 32(1):10-19.
25. McGuinness M.C., Zhang H.P., Smith K.D. Evaluation of pharmacological induction of fatty acid beta-oxidation in X-linked adrenoleukodystrophy. Mol Genet Metab Sep-Oct 2001, 74(1-2):256-263.
26. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A Oct 25 2005, 102(43):15545-15550.
27. Bing O.H., Brooks W.W., Robinson K.G., Slawsky M.T., Hayes J.A., Litwin S.E., et al. The spontaneously hypertensive rat as a model of the transition from compensated left ventricular hypertrophy to failure. J Mol Cell Cardiol Jan 1995, 27(1):383-396.
28. Conrad C.H., Brooks W.W., Hayes J.A., Sen S., Robinson K.G., Bing O.H. Myocardial fibrosis and stiffness with hypertrophy and heart failure in the spontaneously hypertensive rat. Circulation Jan 1 1995, 91(1):161-170.
29. Benjamini Y.H.Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Statistical Soc B 1995, 57:289-300.
30. Takahashi N., Calderone A., Izzo N.J., Maki T.M., Marsh J.D., Colucci W.S. Hypertrophic stimuli induce transforming growth factor-beta 1 expression in rat ventricular myocytes. J Clin Invest Oct 1994, 94(4):1470-1476.
31. Siwik D.A., Chang D.L., Colucci W.S. Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res Jun 23 2000, 86(12):1259-1265.
32. Marin-Garcia J., Goldenthal M.J. Mitochondrial centrality in heart failure. Heart Fail Rev Jun 2008, 13(2):137-150.
33. Giles T.D. Renin-angiotensin system modulation for treatment and prevention of cardiovascular diseases: toward an optimal therapeutic strategy. Rev Cardiovasc Med 2007, 8(Suppl 2):S14-S21.
34. Brower G.L., Levick S.P., Janicki J.S. Inhibition of matrix metalloproteinase activity by ACE inhibitors prevents left ventricular remodeling in a rat model of heart failure. Am J Physiol Heart Circ Physiol Jun 2007, 292(6):H3057-H3064.
35. Jin H., Yang R., Awad T.A., Wang F., Li W., Williams S.P., et al. Effects of early angiotensin-converting enzyme inhibition on cardiac gene expression after acute myocardial infarction. Circulation Feb 6 2001, 103(5):736-742.
36. Frey N., Olson E.N. Modulating cardiac hypertrophy by manipulating myocardial lipid metabolism?. Circulation Mar 12 2002, 105(10):1152-1154.
37. Taegtmeyer H., Wilson C.R., Razeghi P., Sharma S. Metabolic energetics and genetics in the heart. Ann N Y Acad Sci Jun 2005, 1047:208-218.
38. Finck B.N., Kelly D.P. Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) regulatory cascade in cardiac physiology and disease. Circulation May 15 2007, 115(19):2540-2548.
39. de Wilde J., Mohren R., van den Berg S., Boekschoten M., Dijk K.W., de Groot P., et al. Short-term high fat-feeding results in morphological and metabolic adaptations in the skeletal muscle of C57BL/6J mice. Physiol Genomics Feb 19 2008, 32(3):360-369.
40. Rauchhaus M., Doehner W., Francis D.P., Davos C., Kemp M., Liebenthal C., et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation Dec 19 2000, 102(25):3060-3067.
41. Sivakumar P., Gupta S., Sarkar S., Sen S. Upregulation of lysyl oxidase and MMPs during cardiac remodeling in human dilated cardiomyopathy. Mol Cell Biochem Jan 2008, 307(1-2):159-167.
42. Bergman M.R., Kao R.H., McCune S.A., Holycross B.J. Myocardial tumor necrosis factor-alpha secretion in hypertensive and heart failure-prone rats. Am J Physiol Aug 1999, 277(2 Pt 2):H543-H550.
43. Chen Y., Park S., Li Y., Missov E., Hou M., Han X., et al. Alterations of gene expression in failing myocardium following left ventricular assist device support. Physiol Genomics Aug 15 2003, 14(3):251-260.
44. Jahanyar J., Joyce D.L., Southard R.E., Loebe M., Noon G.P., Koerner M.M., et al. Decorin-mediated transforming growth factor-beta inhibition ameliorates adverse cardiac remodeling. J Heart Lung Transplant Jan 2007, 26(1):34-40.
45. Sekiguchi K., Tian Q., Ishiyama M., Burchfield J., Gao F., Mann D.L., et al. Inhibition of PPAR-alpha activity in mice with cardiac-restricted expression of tumor necrosis factor: potential role of TGF-beta/Smad3. Am J Physiol Heart Circ Physiol Mar 2007, 292(3):H1443-H1451.
46. Rishikof D.C., Ricupero D.A., Liu H., Goldstein R.H. Phenylbutyrate decreases type I collagen production in human lung fibroblasts. J Cell Biochem Mar 1 2004, 91(4):740-748.
47. Kang H.L., Benzer S., Min K.T. Life extension in Drosophila by feeding a drug. Proc Natl Acad Sci U S A Jan 22 2002, 99(2):838-843.
48. Gardian G., Browne S.E., Choi D.K., Klivenyi P., Gregorio J., Kubilus J.K., et al. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J Biol Chem Jan 7 2005, 280(1):556-563.
49. Wright J.M., Zeitlin P.L., Cebotaru L., Guggino S.E., Guggino W.B. Gene expression profile analysis of 4-phenylbutyrate treatment of IB3-1 bronchial epithelial cell line demonstrates a major influence on heat-shock proteins. Physiol Genomics Jan 15 2004, 16(2):204-211.
50. Kee H.J., Sohn I.S., Nam K.I., Park J.E., Qian Y.R., Yin Z., et al. Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation Jan 3 2006, 113(1):51-59.
51. Singh O.V., Vij N., Mogayzel P.J., Jozwik C., Pollard H.B., Zeitlin P.L. Pharmacoproteomics of 4-phenylbutyrate-treated IB3-1 cystic fibrosis bronchial epithelial cells. J Proteome Res Mar 2006, 5(3):562-571.
52. Bing O.H., Fanburg B.L., Brooks W.W., Matsushita S. The effect of lathyrogen beta-amino proprionitrile (BAPN) on the mechanical properties of experimentally hypertrophied rat cardiac muscle. Circ Res Oct 1978, 43(4):632-637.
53. Cheng X.W., Obata K., Kuzuya M., Izawa H., Nakamura K., Asai E., et al. Elastolytic cathepsin induction/activation system exists in myocardium and is upregulated in hypertensive heart failure. Hypertension Nov 2006, 48(5):979-987.
54. Khairallah R.J., Khairallah M., Gelinas R., Bouchard B., Young M.E., Allen B.G., et al. Cyclic GMP signaling in cardiomyocytes modulates fatty acid trafficking and prevents triglyceride accumulation. J Mol Cell Cardiol Aug 2008, 45(2):230-239.
55. Yamauchi S., Takeishi Y., Minamihaba O., Arimoto T., Hirono O., Takahashi H., et al. Angiotensin-converting enzyme inhibition improves cardiac fatty acid metabolism in patients with congestive heart failure. Nucl Med Commun Aug 2003, 24(8):901-906.